Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Nguyen H. Tran | Andreas C. Themistocleous | P. Klenerman | J. Knight | T. Wrin | C. Petropoulos | G. Screaton | A. Mentzer | K. Pfafferott | Liaquat A. Khan | K. Ford | Catherine C. Smith | A. Pollard | P. Aley | B. Angus | A. Lawrie | C. Munro | M. Voysey | A. Hill | M. Carroll | J. Furze | H. Humphries | A. Boyd | M. Wand | S. Lipworth | Dimitra Pipini | I. Chelysheva | K. Jeffery | L. Silva-Reyes | M. Snape | Kathryn L. Jones | A. Tahiri-Alaoui | J. Tree | A. Schmid | D. Pulido | P. Matthews | Yanchun Peng | C. Dold | S. Dunachie | J. Frater | C. Conlon | T. Dong | Y. Mujadidi | H. Sharpe | T. Lambe | M. Baker | N. Coombes | K. Bewley | K. Buttigieg | P. Folegatti | K. Ewer | D. Bellamy | S. Bibi | M. Bittaye | E. Clutterbuck | A. Flaxman | B. Hallis | D. Jenkin | A. Minassian | M. Ramasamy | H. Robinson | R. Tarrant | Catherine M. Green | E. Allen | R. Anslow | E. Arbe-Barnes | Natalie Baker | P. Baker | Ioana Baleanu | J. Barrett | Alexander Batten | Kirsten Beadon | E. Berrie | E. Bijker | L. Blackwell | Caitlin L. Blundell | Emma Bolam | E. Boland | N. Borthwick | T. Brenner | Emily Brunt | J. Burbage | Nicholas Byard | F. Cappuccini | J. Cho | L. Cifuentes | Rachel Colin-Jones | C. Cunningham | B. Damratoski | M. Datoo | Hannah Davies | T. Demissie | Claudio Di Maso | F. Donnellan | N. Douglas | Charlotte Downing | Jonathan Drake | R. Drake-Brockman | R. Drury | N. Edwards | M. Elmore | K. Emary | M. English | S. Felle | Samantha M. Field | J. Fowler | E. Francis | Michelle Fuskova | Ciaran Gilbride | K. Godwin | Giacomo Gorini | Lara Gracie | Brama Hanumunthadu | S. Harris | D. Harrison | Jennifer Hill | Mimi M. Hou | Elizabeth Howe | Nicola J. Howell | Poppy Iveson | Susan A. Jackson | Reshma Kailath | J. Keen | Sarah Kelly | D. Kerr | S. Kerridge | Annabel Killen | L. King | Lucy Kingham-Page | Daniel Knott | E. Lees | Alice Lelliott | A. Lias | Aline Linder | Xinxue Liu | Meera Madhavan | Garry Mallett | Kushal Mansatta | S. Marinou | Julia L. Marshall | Joanne Mcewan | Lorna McInroy | Gretchen Meddaugh | N. Mirtorabi | M. Moore | Gertraud Morshead | R. Morter | Sarah Murphy | Philomena Mweu | Andrés Noé | Fay L. Nugent | Elizabeth Nuthall | D. O'connor | B. Oguti | N. Owino | Kaye Parker | Helena Parracho | Maia Patrick-Smith | Marco Polo Peralta Álvarez | E. Plested | I. Poulton | K. Radia | Fernando Ramos Lopez | T. Rawlinson | S. Rhead | A. Ritchie | H. Roberts | S. Roche | C. Rollier | Indra Rudiansyah | Katherine Sanders | Imam H Shaik | S. Silk | D. Skelly | David J. Smith | R. Song | Alexandra J. Spencer | E. Stafford | L. Stockdale | Anna Szigeti | R. Tanner | I. Taylor | Rebecca te Water Naude | Y. Themistocleous | Merin Thomas | Tonia Thomas | A. Thompson | S. Tonks | James Towner | Adam Truby | Cheryl Turner | N. Turner | R. Varughese | M. Verheul | Marion E E Watson | C. White | Rachel White | A. Worth | D. Wright | X. Yao | C. Arancibia-Cárcamo | A. Gorringe | Sean C. Elias | Hazel Morrison | L. Loew | N. Marchevsky | Alexander D. Douglas | Breeze E. Cavell | Richard Fisher | Stephanie Leung | I. Satti | E. Schofield | E. Penn | Yuanyuan Li | S. Gilbert | L. Allen | E. Barnes | M. Carr | Jim Chadwick | Harriet N. Garlant | Gina Hodges | E. Marlow | J. McGlashan | R. Morgans | E. Mukhopadhyay | F. L. Nugent | Pamela C. Proud | M. Ulaszewska | Gaurav Gupta | J. A. Henry | J. Mellors | H. Sanders | D. O’Donnell | Amy Beveridge | Susana Camara | T. King | Joseph Hamlyn | R. Makinson | R. Halkerston | Frederic Jackson | Stephen Taylor | Sandra Belij-Rammerstorfer | A. Themistocleous | R. Cooper | D. Kelly | I. Vichos | J. Aboagye | Aabidah Ali | L. Bates | Rebecca Beckley | Sophia Hawkins | Baktash Khozoee | Jasmin Kinch | S. Koleva | Colin W. Larkworthy | E. Morey | Jill Muller | Laura L Walker | S. Feng | H. Ratcliffe | Jennifer Alderson | Cynthia Sedik | Daniel J. Phillips | Ioana N Baleanu | Emma J Bolam | Ingrid Cabrera Puig | Michelangelo Cao | J. Chadwick | Elizabeth Clark | C. Datta | Pablo Galian-Rubio | Shuchang Liu | Victoria Olchawski | P. Osborne | James Perring | Stephannie Salvador | Adam Shea | P. Williams | Dalila Zizi | E. Jones | A. Tomic | S. Provstgaard-Morys | A. Douglas | Susanne H. Hodgson | R. Lopez Ramon | K. Taylor | Charlie Brown-O’Sullivan | Wendy E. M. Crocker | Jessica P. J. Larwood | S. Morris | Katie O’Brien | P. O’Reilly | Kelly M. Thomas | Danielle DiTirro | Ben Huang | Sam Jauregui | Nathifa Moya | Lan Tinh | Thomas C. Hart | Omar El Muhanna | Catarina Oliveria | Emilia Reyes Pabon | E. Hamilton | Elizabeth Kelly | Jeremy Jennifer Aabidah Elizabeth Lauren Rachel Carolina Aboagye Alderson Ali Allen Allen Anslow Ar | Philip Brown | Carla Ferreira Da Silva | Durga Rajapaksa | H. Davies | M. Hou | S. Hodgson | J. Henry | D. O’Connor | Imam H. Shaik | J. Hill | J. Kinch | Lauren Allen | Miles W. Carroll | Miles W. Carroll | C. Blundell | N. Edwards | A. Tahiri‐Alaoui | N. Byard | Harriet Garlant | Elizabeth J Kelly | Samuel Lipworth | Eleanor Barnes | I. Cabrera Puig | Elizabeth M Hamilton | P. O'reilly | Emma L Plested | Natalie Marchevsky | Daniel Phillips

[1]  Nguyen H. Tran,et al.  T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.

[2]  A. Charlett,et al.  SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers , 2020, medRxiv.

[3]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[4]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[5]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[6]  Mathieu Le Gars,et al.  Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial , 2020, medRxiv.

[7]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[8]  A. Gintsburg,et al.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia , 2020, The Lancet.

[9]  V. Shinde,et al.  Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine , 2020, The New England journal of medicine.

[10]  E. Lesne,et al.  Acellular Pertussis Vaccines Induce Anti-pertactin Bactericidal Antibodies Which Drives the Emergence of Pertactin-Negative Strains , 2020, Frontiers in Microbiology.

[11]  Yongli Yang,et al.  Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. , 2020, JAMA.

[12]  M. Zjalic,et al.  SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury , 2020, Frontiers in Cellular Neuroscience.

[13]  Kira L. Newman,et al.  Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.

[14]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[15]  Andrew T. Levin,et al.  ASSESSING THE AGE SPECIFICITY OF INFECTION FATALITY RATES FOR COVID-19: META-ANALYSIS & PUBLIC POLICY IMPLICATIONS , 2020, medRxiv.

[16]  Y. Hu,et al.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial , 2020, The Lancet.

[17]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[18]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[19]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[20]  D. Lowy,et al.  The COVID-19 Serology Studies Workshop: Recommendations and Challenges , 2020, Immunity.

[21]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[22]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[23]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[24]  P. Sorger,et al.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques , 2020, Science.

[25]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[26]  H. Schuitemaker,et al.  Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older. , 2020, The Journal of infectious diseases.

[27]  M. Addo,et al.  Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial , 2020, The Lancet Infectious Diseases.

[28]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[29]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[30]  Philip L. Felgner,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.

[31]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[32]  L. Aniksztejn,et al.  The Epilepsy of Infancy With Migrating Focal Seizures: Identification of de novo Mutations of the KCNT2 Gene That Exert Inhibitory Effects on the Corresponding Heteromeric KNa1.1/KNa1.2 Potassium Channel , 2020, Frontiers in Cellular Neuroscience.

[33]  G. Alter,et al.  A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.

[34]  S. Kapiga,et al.  Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania , 2019, The Journal of infectious diseases.

[35]  E. Reisinger,et al.  Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial , 2018, The Lancet.

[36]  K. Knox,et al.  Development of flow cytometric opsonophagocytosis and antibody-mediated complement deposition assays for non-typeable Haemophilus influenzae , 2018, BMC Microbiology.

[37]  Galit Alter,et al.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) , 2018, The Lancet.

[38]  A. Preston,et al.  Bordetella pertussis isolates vary in their interactions with human complement components , 2018, Emerging Microbes & Infections.

[39]  Juliana K. Wambua,et al.  Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. , 2017, JCI insight.

[40]  J. McCarthy,et al.  Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies , 2017, JCI insight.

[41]  H. Humphries,et al.  Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort , 2017, Vaccine.

[42]  J. Mascola,et al.  Chimpanzee Adenovirus Vector Ebola Vaccine , 2017, The New England journal of medicine.

[43]  K. Chu,et al.  Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. , 2017, The Lancet. Global health.

[44]  Roger D. Cox,et al.  Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy , 2017, JCI insight.

[45]  A. Hill,et al.  Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure , 2014, PloS one.

[46]  A. Nicosia,et al.  Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  Jerome H. Kim,et al.  Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines , 2014, Clinical and Vaccine Immunology.

[48]  A. Osterhaus.  Faculty Opinions recommendation of Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. , 2014 .

[49]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[50]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[51]  C. Bailey-Kellogg,et al.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.

[52]  K. Bojang,et al.  A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.

[53]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[54]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[55]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[56]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[57]  C. Lutz,et al.  Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy1 , 2008, The Journal of Immunology.

[58]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[59]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[61]  E. Collisson,et al.  Adoptive Transfer of Infectious Bronchitis Virus Primed αβ T Cells Bearing CD8 Antigen Protects Chicks from Acute Infection , 2000, Virology.

[62]  D. Zurakowski,et al.  A statistically defined endpoint titer determination method for immunoassays. , 1998, Journal of immunological methods.

[63]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.